版本:
中国

BRIEF-Immunovaccine announces positive interim clinical data from Ovarian cancer study

March 29 Immunovaccine Inc:

* Immunovaccine announces positive interim clinical data from ovarian cancer study of DPX-survivac in combination with epacadostat

* Immunovaccine Inc - based on interim analysis, combination therapy appears to have an acceptable safety profile

* Immunovaccine - at time of interim analysis, 3 of 4 patients exhibited stable disease, while fourth patient continued to progress and discontinued trial

* Immunovaccine Inc - expects to complete enrollment and issue topline data by end of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐